Protocol Ledger

NCT04025632 · Phase II · TERMINATED

Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy

Interventional Phase II clinical trial protocol NCT04025632 sponsored by UCB in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-11-07 Enrollment: 27 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04025632
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)27 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04025632
Protocol FieldVerified Registry Value
NCT IdentifierNCT04025632
Consolidated Lead SponsorUCB
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment27 participants (ACTUAL)
Registered Start Date2019-11-07
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for UCB across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI